Review
Unsolved questions and concerns about treatment of anti-neutrophil cytoplasm antibody-associated vasculitides
B. Chaigne1, L. Guillevin2
- Department of Internal Medicine, National Referral Center for Rare Autoimmune and Systemic Diseases, INSERM U1016, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, University of Paris Descartes, Paris, France.
- Department of Internal Medicine, National Referral Center for Rare Autoimmune and Systemic Diseases, INSERM U1016, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, University of Paris Descartes, Paris, France. loic.guillevin@cch.aphp.fr
CER9414
2016 Vol.34, N°3 ,Suppl.97
PI 0121, PF 0128
Review
Free to view
(click on article PDF icon to read the article)
PMID: 27087528 [PubMed]
Received: 08/03/2016
Accepted : 05/04/2016
In Press: 13/04/2016
Published: 27/05/2016
Abstract
The treatment strategy for vasculitis has changed dramatically over the last few years, but some major questions remain. Herein, after reviewing the literature, we provide answers to, or at least an analysis of, available evidence on 10 specific and practical questions concerning ANCA-associated vasculitis management.
